Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Neoplasms × maltodextrin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vaso-Occlusive Crises 1 Neoplasms 1 Diarrhea 1 Anemia, Sickle Cell 1

Interventions

pembrolizumab 109 Paclitaxel 85 Gemcitabine 82 Carboplatin 72 Nivolumab 55 Docetaxel 54 Bevacizumab 53 Cisplatin 44 Pemetrexed 42 Fluorouracil 40 Cyclophosphamide 38 Cetuximab 31 Capecitabine 31 Leucovorin 30 venetoclax 29 Irinotecan 29 atezolizumab 28 Sorafenib 28 trametinib 27 Erlotinib Hydrochloride 26 Dexamethasone 25 130-nm albumin-bound paclitaxel 25 Drug Therapy 24 Ipilimumab 23 Epoetin Alfa 23 Doxorubicin 22 Oxaliplatin 20 Lapatinib 19 Rituximab 18 Prednisone 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02819960 2022-12-14

Prevention of Irinotecan Induced Diarrhea by Probiotics

S&D Pharma SK s.r.o.

Phase 3 Completed

Diarrhea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡